Related Experiment Video

Updated: Mar 15, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

13.1K

Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways

Anjali Roy1, Mansi Srivastava1, Uzma Saqib2

  • 1Center for Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology (IIT), Indore, MP, India.

International Immunopharmacology
|September 2, 2016
PubMed

Insights

Toll-like receptor 4 (TLR4) signaling drives inflammation in chronic diseases. Inhibiting TLR4 pathway targets offers a therapeutic strategy for inflammatory disorders.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Inflammation is a critical immune response to infection or injury, requiring tight regulation to prevent host damage.
  • Imbalances in inflammatory responses are linked to various chronic diseases.
  • Toll-like receptors (TLRs), particularly TLR4, are implicated in the pathogenesis of chronic inflammatory conditions.

Purpose of the Study:

  • To review potential therapeutic targets within the TLR4 signaling pathway.
  • To explore strategies for suppressing chronic inflammatory disorders by targeting TLR4.

Main Methods:

  • Literature review of studies investigating TLR4 signaling in inflammation.
  • Analysis of transcription factors activated by TLR4, including NF-κB, AP1, STAT1, and IRFs.
  • Identification of upstream signaling molecules as potential therapeutic targets.

Main Results:

  • TLR4 activation induces inflammatory gene expression.
  • TLR4 signaling activates key transcription factors (NF-κB, AP1, STAT1, IRFs) regulating inflammatory responses.
  • Inhibiting TLR4 and its downstream pathways presents a viable therapeutic approach.

Conclusions:

  • Targeting TLR4 signaling pathways is crucial for managing chronic inflammatory diseases.
  • Interfering with TLR4 and its associated transcription factors offers a promising therapeutic avenue.
  • Further research into TLR4 pathway inhibition could lead to novel treatments for inflammatory disorders.
Keywords:
AP1IRF'sInflammationNF-κBSTAT1TLR4 signaling

More Related Videos

A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces07:55

A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces

Published on: January 7, 2020

7.9K
In Vivo Two-Color 2-Photon Imaging of Genetically-Tagged Reporter Cells in the Skin05:45

In Vivo Two-Color 2-Photon Imaging of Genetically-Tagged Reporter Cells in the Skin

Published on: July 11, 2019

8.0K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
18.1K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.2K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
697
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
895